STRUCTURE AND EXPRESSION OF SUPPRESSOR T CELL PRODUCTS

T细胞对卵巢癌的发育和调节是绝对必要的。 免疫反应，并因此对维持健康。我们的 T细胞亚群的多样性和生物活性的知识是 广泛存在；然而，人们对T细胞的结构知之甚少 受体和T细胞介体。这项建议的目标是 分离、纯化和鉴定抗原特异性因子和受体 由抑制性T细胞的不同亚群表达。我们的战略是 分析小鼠抑制性T细胞产物是为了发展T细胞 杂交瘤筛选类似抑制子的抑制子活性 正常T细胞的活性。我们已经生产了一大块T细胞面板 杂交瘤很可能含有至少四个不同的T细胞 子集。这些杂交瘤产生的因子具有抗原结合位点。 并携带由H-2基因复合体编码的决定因素。六种不同的H-2 单倍型在此面板中显示。我们建议将T刻画为 这些杂交瘤的细胞产物使用功能血清学， 免疫化学和生化技术。我们的具体目标是 确定一个原型抑制子的结构和氨基酸序列 我们已经提纯为同质的因子。选定的T之间的比较 细胞杂交瘤产品将揭示结构同源性的程度 在密切相关的分子家族的成员之间。我们将发展 免疫T细胞杂交瘤或纯化的新血清学试剂 杂交瘤产品。这些血清和单克隆抗体将用于 鉴定新的I区基因产物，并验证因子和 T细胞杂交瘤产生的受体由类似的、正常的 体内的调节性T细胞。这些研究最终应该会导致 识别所有基本的、相互作用的T细胞亚群 抗原特异性抑制通路。此外，有关 参与抑制T细胞活性的基因的数量和性质可以 用这些抑制性T细胞杂交瘤来接近。

T cells are absolutely essential to the development and regulation of immune responses and consequently to the maintenance of health. Our knowledge of the diversity and biological activity of T cell subsets is extensive; yet, very little is known about the structure of T cell receptors and T cell mediators. The objectives of this proposal are to isolate, purify, and characterize antigen-specific factors and receptors expressed by various subsets of suppressor T cells. Our strategy for the analysis of murine suppressor T cell products was to develop T cell hybridomas by screening for suppressor activities analogous to suppressor activities of normal T cells. We have produced a large panel of T cell hybridomas that very likely contains a minimum of four distinctive T cell subsets. Factors produced by these hybridomas have antigen-binding sites and bear determinants encoded by the H-2 gene complex. Six different H-2 haplotypes are represented in this panel. We propose to characterize T cell products from these hybridomas using functional serological, immunochemical and biochemical techniques. Our specific aims are to determine the structure and amino acid sequence of a prototype suppressor factor which we have purified to homogeneity. Comparisons among selected T cell hybridoma products will reveal the degree of structural homology between members of a family of closely related molecules. We will develop new serological reagents by immunization with T cell hybridomas or purified hybridoma products. These sera and mono-lonal antibodies will be used to identify new I-region gene products and to verify that factors and receptors produced by T cell hybridomas are expressed by analogous, normal regulatory T cells in vivo. These studies should eventually lead to the identification of all essential, interacting T cell subsets in one antigen-specific suppressor pathway. In addition, questions concerning the number and nature of the genes involved in suppressor T cell activity can be approached using these suppressor T cell hybridomas.